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Background: The belief remains widespread that medical research studies must have statistical power of at least
80% in order to be scientifically sound, and peer reviewers often question whether power is high enough.
Discussion: This requirement and the methods for meeting it have severe flaws. Notably, the true nature of how
sample size influences a study’s projected scientific or practical value precludes any meaningful blanket designation
of <80% power as “inadequate”. In addition, standard calculations are inherently unreliable, and focusing only on
power neglects a completed study’s most important results: estimates and confidence intervals. Current
conventions harm the research process in many ways: promoting misinterpretation of completed studies, eroding
scientific integrity, giving reviewers arbitrary power, inhibiting innovation, perverting ethical standards, wasting
effort, and wasting money. Medical research would benefit from alternative approaches, including established value
of information methods, simple choices based on cost or feasibility that have recently been justified, sensitivity
analyses that examine a meaningful array of possible findings, and following previous analogous studies. To
promote more rational approaches, research training should cover the issues presented here, peer reviewers should
be extremely careful before raising issues of “inadequate” sample size, and reports of completed studies should not
discuss power.
Summary: Common conventions and expectations concerning sample size are deeply flawed, cause serious harm
to the research process, and should be replaced by more rational alternatives.
Background
Early in my career, an epidemiologist told me that deal-
ing with sample size is the price one has to pay for
being a biostatistician. Since then, I have spent untold
time and effort paying this price, while also coming to
realize that such effort produces no real scientific bene-
fit. Unfortunately, widespread misconceptions about
sample size hurt not only statisticians, but also the qual-
ity of medical science generally.
The conventional expectation is that a study must
have at least 80% power or else be considered scientifi-
cally unsound and even unethical [1]. Some challenges
to this dogma have been based on the idea that some
information is better than none and that even a small
amount of inconclusive information may contribute to a
later systematic review [2-4], but conventions remain
entrenched and failing to anticipate systematic reviews
is only one aspect of only one of three fundamental
flaws. I present here a wider challenge to current con-
ventions, including how they cause serious harm. Alter-
natives could produce both better studies and fairer
peer review of proposed studies.
Discussion
Flaws in current conventions
The standard approach is based on statistical hypothesis
testing where one rejects a null hypothesis of no differ-
ence if the P-value is < 0.05. One calculates sample size
based on a specified difference of interest, an assump-
tion about the standard deviation or event rate of the
outcome being studied, and conventional choices for
Type I error (chance of rejecting the null hypothesis if it
is true) and statistical power (chance of rejecting the
null hypothesis if the specified difference actually exists).
Type I error is essentially always set to be 0.05, and
sample sizes producing power less than 80% are consid-
ered inadequate. Three crucial flaws in this standard
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between adequate and inadequate sample sizes that does
not actually exist, not even approximately; 2) relies
strongly on inputs that generally cannot be accurately
specified; and 3) does not reflect how a completed
study’s information should actually be used. Although
the first is perhaps the most fundamental, all three are
severe, and they intertwine to produce many of the
harms discussed in the next section.
Experience with previous related papers suggests that
many readers will immediately formulate objections or
counterarguments. Anticipating and pre-empting all
these is not possible, but I comment on two of the
more likely ones in Additional file 1.
The threshold myth
Current conventions hinge on an implicit assumption
that there is a meaningful demarcation between ade-
quate and inadequate sample sizes, and that having an
inadequate sample size is fatal. I find this consistently
reflected in the language used by my clients, collabora-
tors, and colleagues: asking how many will be “needed
to answer the question”, wanting to ensure they will
“have enough subjects,” and calling studies with <80%
power “doomed” and therefore wasteful and unethical.
A statement from a recent grant review is very typical
in presuming that too small a sample size could comple-
tely ruin the study: “it is unclear if the study will be suf-
ficiently powered to allow the proposed analyses.” If
there were an approximately threshold-shaped relation-
ship between sample size and the scientific or practical
value that a study can be projected to produce, as
shown in Figure 1, then this implicit assumption would
be reasonable: falling short of the threshold would
indeed result in an inadequate study. Such a shape is
also needed to justify the practice of ignoring costs
when setting sample size: if the correct side of the
threshold were always where 80% power is produced,
then current methods would automatically produce a
good cost-benefit tradeoff without explicitly considering
costs. Unfortunately for the standard approach, the real
relationship is radically different from a threshold,
instead having a concave shape that continually flattens,
reflecting diminishing marginal returns. This character-
istic shape was recently verified for a wide variety of
measures of projected value that have been proposed for
use in sample size planning, including power [5]. Falling
short of any particular arbitrary goal, notably 80%
power, is therefore not the calamity presumed by con-
ventional thinking. The lack of any threshold undercuts
the foundation of current standards: they guard against
a non-existent danger.
Inherent inaccuracy
Although precise mathematical formulas are available
for calculating sample sizes, these depend on specifying
exact values for inputs, and changes in these inputs pro-
duce magnified changes in the resulting sample size. In
particular, studies with a continuous primary outcome
measure, such as quality of life score, change in telo-
mere length, weight loss, and so on, must specify its
standard deviation. This is difficult to do accurately,
unless there is so much preliminary data that the study
isn’t really needed, but it has a big influence on sample
size: a two-fold increase in the assumed standard devia-
tion produces a four-fold increase in sample size.
A four-fold larger sample size also results from halving
the difference of interest (the alternative hypothesis).
This is particularly hard to specify because even the the-
oretical principles for choosing it are unclear. Some
assert that it should be the smallest difference that
would be important to patients or for scientific or public
health purposes [1], but this is often subjective and diffi-
cult to specify (what difference in survival rates is unim-
portant), importance is rarely all-or-nothing, and very
small differences may be important, leading to impracti-
cal sample sizes. Investigators frequently use the differ-
ence suggested by preliminary data, but this is
unreliable [6] and has greater risk of inconclusive results
for differences that are smaller but still interesting.
A case has even been made for using the difference
hoped for by patients [7].
Inaccuracy of sample size calculations is not only the-
oretically inevitable [6,8] but also empirically verified.
One careful study of assumed standard deviations in a
seemingly best-case scenario, randomized trials
Figure 1 Qualitative depiction of how sample size influences a
study’s projected scientific and/or practical value. A threshold
shaped relationship (dashed line) would create a meaningful
distinction between adequate and inadequate sample sizes, but
such a relation does not exist. The reality (solid line) is qualitatively
different, exhibiting diminishing marginal returns. Under the
threshold myth, cutting a sample size in half could easily change a
valuable study into an inadequate one, but in reality such a cut will
always preserve more than half of the projected value.
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found that about a quarter had more than five-fold inac-
curacy in sample size and more than half had more than
two-fold inaccuracy [9]. Another study recently found
high rates of inaccuracy along with many other pro-
blems [10]. This problem cannot be solved by simply
trying harder to pinpoint where 80% power will be
achieved, because inaccuracy is inherent in the conven-
tional framework.
Design-use mismatch
Why design a study as if the only thing you will exam-
i n ew h e ni ti sd o n ei sw h e t h e ro rn o tP < 0.05? Good
statistical practice demands consideration of the particu-
lar P-value obtained and, more importantly, of estimates
and confidence intervals that quantify the effects or
associations of interest [11,12]. Using a P-value cutoff to
define a study as positive or negative was proposed as a
framework for using a single study in isolation to auto-
matically make a decision ab o u tw h a tt od o[ 1 3 ] ,b u t
this framework is rarely actually followed in medical
research. Even pivotal randomized drug trials must pro-
vide convincing evidence, not just an automatic deci-
sion: regulators would never settle for knowing nothing
about a study’s results other than P < 0.05. In addition,
much of the value of an individual study may derive
from its contribution to later systematic reviews [2-4],
which will not make any use of the study’s P-value.
Planning for a use that will not (or should not) occur
cannot be expected to optimize a study’s design. (Impor-
tantly, the threshold myth and inherent inaccuracy
remain severe problems even for the rare cases where a
study is likely to be the sole basis for making an auto-
matic decision based only on whether P < 0.05.)
Harms from current conventions
Because of the reality illustrated in Figure 1, the choice
of sample size is less important than generally supposed.
Much of the substantial harm from current conventions
therefore results not from bad sample size choices but
from unrealistic expectations and strict enforcement of
misguided standards.
False assurance and promotion of misinterpretation
The idea that a carefully chosen “adequate” sample size
can ensure that a study will be definitive, reflected in
the common phrase “enough to answer the question”,i s
certainly appealing, but it is just wishful thinking. In
addition to inherent inaccuracy and the fact that an 80%
chance is far from a certainty, even huge studies can
produce results near the boundary of what is large
enough to be important. For example, a mega-study of
the influence of dietary fat intake on breast cancer risk
[14] produced an estimated effect part way between
what had been expected and no effect. Far from ensur-
ing that a study will be definitive, claims of 80% power
actually provide no information about how valuable any
particular study is likely to be, because every proposal
contains such a claim.
False assurance leads directly to the following logic:
“S a m p l es i z ei sa d e q u a t et oe n s u r ead e f i n i t i v er e s u l t ,
the result is not definitively positive (that is, P > 0.05),
therefore the result is definitively negative.” Ih a v e
encountered many researchers who believe this logic,
and the widespread practice of considering power when
interpreting so-called negative studies [15] seems aimed
at determining when this reasoning can be applied. This
resolves the design-use mismatch, but in the wrong way,
by focusing only on whether P < 0.05. Although investi-
gators usually report estimates, confidence intervals, and
attained P-values, they often ignore these very informa-
tive results when interpreting their studies. For example,
a study of vitamin C and E supplementation in preg-
nancy reported rates of infant death or other serious
outcomes that implied one outcome prevented for every
39 women treated [16]. The authors nevertheless con-
cluded definitively that supplementation “does not
reduce the rate”,b e c a u s et h eP-value was 0.07. Inter-
preting P > 0.05 as indicating that the results actually
observed must be an illusion is very poor reasoning, but
I find it in most draft manuscripts I review and many
published articles I read. Interpretation of P <0 . 0 5a s
ensuring that an observed effect is real and accurate
also seems to be widespread, despite being unreliable
[17].
Erosion of scientific integrity
Manipulation of sample size calculations to produce a
desired result is a well-acknowledged phenomenon
[3,18,19] that has been described as a “sample size
game” [20] or “sample size samba” [21]. A published
dramatization of the process ends with the statistician
asking a client, “Where do you want to start fudging?”
[22] Changing the specified difference of interest makes
such manipulation easy, and unavoidable practical reali-
ties often make it necessary, either because cost or feasi-
bility constraints cannot be exceeded or because there is
not enough information about inputs to permit a mean-
ingful calculation. Sample size is then chosen based on
other criteria, but it must still be justified in terms of
power. Forcing investigators to hide the real reason for
choosing a sample size sends a bad message about
integrity, right at the beginning of the research process.
Arbitrary reviewer power
Because of the strong reliance on uncertain inputs, any
reviewer who is so inclined can question the assump-
tions and results of any power calculation. A minor
change in the inputs can indicate that the proposed
sample size falls substantially short of “adequate”.
Whether a sample size justification passes peer review
therefore depends on arbitrary reviewer discretion,
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Because criticism of sample size plans is always possible
and very common [23], it is ideal for providing cover
when reviewers cannot pinpoint, or are unwilling to
admit, the real reasons why they dislike a proposal.
Barrier to innovation
Proposals to evaluate new ideas or issues face particular
difficulty, because the lack of adequate knowledge about
inputs for standard calculations is especially obvious.
Although a National Institutes of Health task force on
peer review argued that no preliminary data should be
required for new ideas [24], this does not solve the pro-
blem of justifying a sample size. Innovators must usually
rely on guesses that are obviously arbitrary or provide
calculations based on standardized effect sizes that have
no real connection to the study being proposed. This
leaves them especially vulnerable to the arbitrary
reviewer power noted above.
Wrong-way ethical standards
The contention that inadequate power makes a study
unethical [1] relies entirely on the threshold myth, a
false belief that studies with less than 80% power cannot
be expected to produce enough scientific or practical
value to justify the burden imposed on participants.
Because larger studies burden more participants, the
fact of diminishing marginal returns implies that the
ratio of projected value to total participant burden can
only get worse with larger sample sizes. The risk of
inadequate projected value relative to participant burden
therefore applies to studies that are too large, not too
small [25-27].
Wasted effort
Because conventional sample size planning produces no
real benefit, it wastes time and talent. Investigators often
struggle to understand what is needed for calculations,
to find even semi-relevant preliminary data, and to
somehow formulate and justify seemingly arbitrary
guesses and choices. Statisticians often help with all of
the above, determine appropriate simplifications and
approximations, and painstakingly piece together rele-
vant inputs from published graphs or partial informa-
tion. This reduces time and effort available for
producing real scientific value.
Wasted money
Without the threshold myth, it makes no sense to set a
sample size goal that must be reached regardless of cost,
but cost has no role in the standard approach. Ignoring
costs is so impractical that investigators may often take
them into account. Actually following the conventional
approach can produce severely cost-inefficient sample
size choices [5]. In addition, the threshold myth pro-
motes a default strategy of concentrating more resources
in fewer, larger studies [28]. Such concentration can be
efficient if the funded studies are much more promising
than their competitors [29], but concentration will be
inefficient whenever there are many possible studies
with similar promise or when reviewers nix small but
cost-efficient studies for having supposedly inadequate
sample sizes. Concentration may be particularly poor
when allocating limited patients among competing stu-
dies, because adding more patients to an already-large
study not only produces less and less incremental value
but also takes away more and more potential value from
other studies: diminishing marginal returns imply
increasing marginal opportunity costs.
Alternatives
Abandoning the 80% power standard need not lead to
sample size nihilism, where “we abandon the current
delusion that sample size matters” [3]. There are meth-
ods for making sensible sample size decisions while
avoiding the drawbacks of current conventions.
Value of information methods
Many methods have already been described in the statis-
tical literature for choosing the sample size that maxi-
mizes the expected value of the information produced
minus the total cost of the study. See [18] for an early
discussion, [30,31] for recent examples, and the intro-
duction of [5] for additional references. These require
projecting both value and cost at various different sam-
ple sizes, including quantifying cost and value on the
same scale (note, however, that this could be avoided by
instead maximizing value divided by total cost). They
also require formally specifying uncertainty about the
state of nature; although this can be criticized as being
subjective, it improves vastly on the usual conventional
approach of assuming that one particular guess is accu-
rate. These methods can require considerable effort and
technical expertise, but they can also produce the sort
of thorough and directly meaningful assessment that
should be required to justify studies that are very expen-
sive or that put many people at risk.
Simple choices based on cost or feasibility
Recent work has justified two simple choices that are
based only on costs [5], with no need to quantify pro-
jected value or current uncertainty about the topic
being studied. Because costs can generally be more
accurately projected than the inputs for conventional
calculations, this avoids the inherent inaccuracy that
besets the conventional approach. One choice, called
nmin, is the sample size that minimizes the total cost per
subject studied. This is guaranteed to be more cost-effi-
cient (produce a better ratio of projected value to cost)
than any larger sample size. It therefore cannot be
validly criticized as inadequate. The other, called nroot,i s
the sample size that minimizes the total cost divided by
the square root of sample size. This is smaller than nmin
and is most justifiable for innovative studies where very
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which case it is also guaranteed to be more cost efficient
than any larger sample size. An interactive spreadsheet
that facilitates identification of nmin and nroot is provided
as Additional file 2.
A common pragmatic strategy is to use the maximum
sample size that is reasonably feasible. When sample
size is constrained by cost barriers, such as exhausting
the pool of the most easily studied subjects, this strategy
may closely approximate use of nmin and therefore share
its justification. When constraints imposed by funders
determine feasibility, doing the maximum possible
within those constraints is a sensible choice.
Sensitivity analysis
Sample size planning involves considerable uncertainty,
and a simple and familiar way of assessing uncertainty is
with sensitivity analyses: examining how results change
under different assumptions. I propose a framework,
illustrated in Table 1, for presenting a useful array of
possibilities for a study’s most important products, the
estimated effect and its confidence interval. This is
based on varying 1) assumptions that determine the pre-
cision of estimates and 2) the observed effect size.
Together with discussion of the potential value of each
resulting outcome, this provides an informal assessment
of the value of the information that may result. This is
less systematic than the value of information methods
mentioned above, but it covers a range of likely scenar-
ios, avoids technical difficulties of the mathematically
formalized methods, and focuses on particular concrete
results, which allows reviewers to easily assess the
claimed potential value. Because the table entries show
the information that would be used in a systematic
review, the potential value can be discussed in terms of
how it would modify a recent review or contribute to
future ones, if those are deemed to be the most impor-
tant considerations.
The entries in the table are exactly the key results that
interpretation should focus on when the study is com-
pleted, so this properly aligns planning with eventual
use. The middle row can be a best guess such as would
be used for conventional calculations; the other rows
should reflect a reasonable range of uncertainty, which
will depend on what is already known about the topic
being studied. For the columns, inclusion of the inter-
mediate case is important, because this will often
include the most problematic or disappointing potential
results. The vitamin study [16] paired a safe and inex-
pensive intervention with a severe outcome, so even
results in the middle column would be regarded as
encouraging; the actual completed study landed essen-
tially in Box 7, which should have been interpreted as
very encouraging even though not definitive. Boxes 8
and 9 will usually be the least useful, but as noted above
(False assurance), the risk of disappointing results is
always present and should not be considered a flaw in
study design.
Previous similar or analogous studies
A simple way to choose a sample size is to use one that
has worked well in the past for similar or analogous stu-
dies. Because exactly relevant preliminary data are often
unavailable, assumptions for power calculations are fre-
quently based on such studies, anyway. Skipping the
over-formalized and inherently unstable power calcula-
tion process and just using the previous sample size
may be a reasonable approach.
Getting there from here
The culture around sample size planning seems to be
extraordinarily entrenched, so change may be difficult.
Nevertheless, the following actions could help move
medical research toward more rational expectations.
Research training should not present current conven-
tions as unquestionable dogma. Although trainees must
know about the culture they will have to face, education
about sample size should be balanced. For example, this
article could be discussed.
When preparing a study proposal, courageous investi-
gators could use an alternative approach from the pre-
vious section. This may be most practical for highly
Table 1 Sample layout of sensitivity analysis.




























Shown are possible study results with a given sample size (935 per group, based on the vitamin study discussed above [16]), for a yes or no outcome. Rows have
differing assumptions concerning precision of the estimates, ranging from high precision (top row) to low precision (bottom row). For a continuous outcome, the
rows would instead be for optimistic (small), expected, and pessimistic (large) standard deviations.
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would most clearly be meaningless. For other studies,
use of detailed value of information methods may be
convincing when the effort they require can be devoted.
In many cases, it may be safer to supplement standard
power calculations with more meaningful reasoning
regarding sample size. This avoids dishonesty and at
least gives reviewers the option of focusing on what
really matters. Also, the juxtaposition of standard and
alternative reasoning may help promote recognition of
the standard approach’s inadequacies.
Stemming criticism of sample size in the peer review
process is necessary to allow alternative approaches to
take hold. Reviewers should usually refrain from criticiz-
ing sample size and should challenge fellow reviewers
who do. If fellow reviewers feel that a study is only half
as large as it should be, remind them that this does not
mean that the study is doomed to be worthless; instead,
it will have more than half the projected value that it
would with the doubled size. Sample size criticism is
currently too easy and convenient; challenging fellow
reviewers will help to change this.
Reports of completed studies should not include
power calculations, and guidelines requiring them [11]
should be changed to instead discourage them. Report-
ing power calculations has been justified as a way to dis-
close the primary outcome and the original target
sample size [21,32], but these can be stated directly
without any reference to a power calculation [33].
Because power calculations are often not the real reason
for the chosen sample size,p r o v i d i n gt h e mf o rc o m -
pleted studies does not promote, but rather subverts,
full, transparent reporting. In addition, power is irrele-
vant for interpreting completed studies [15,20,34,35],
because estimates and confidence intervals allow more
direct and reliable interpretation. Reporting power cal-
culations inevitably gives the impression that they mat-
ter for interpretation, which serves to reinforce the
widespread misconception that they allow any result
with P > 0.05 to be interpreted as proving the null
hypothesis [33].
Summary
The status quo concerning sample size is unacceptable
because of severe inherent flaws and substantial harm to
the research process. Perhaps most notably, the thresh-
old myth is clearly unrealistic, but it is an essential
underpinning of the common and pernicious practice of
condemning studies thought to be “underpowered”.
Despite lack of any valid rationale or supporting evi-
dence, current conventions are so deeply entrenched
and widely enforced that inertia alone may perpetuate
them for some time. I encourage any who are persuaded
by the case presented here to take action to hasten
reform.
Additional file 1: Comments on two possible objections. Discusses
two possible objections to the case made in this paper.
Additional file 2: Cost-based sample size. This is an interactive
Microsoft Excel spreadsheet that facilitates determination of sample sizes
nmin and nroot using the simple cost-based methods noted in the
Alternatives section.
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